

# Recognizing and diagnosing hATTR amyloidosis

**Multisystem involvement should raise suspicion of hATTR amyloidosis and prompt additional investigation.<sup>1,2</sup> A multidisciplinary approach is critical for diagnosis and management.<sup>2,3</sup>**

## RED-FLAG SYMPTOMS AND/OR FAMILY HISTORY<sup>1</sup>



### Sensory-motor neuropathy<sup>1,4,5</sup>

- Pain, tingling
- Altered sensation
- Bilateral carpal tunnel syndrome
- Weakness
- Difficulty walking



### Autonomic neuropathy<sup>1,4,5</sup>

- GI symptoms
- Orthostatic hypotension
- Recurrent UTIs
- Sexual dysfunction



### Cardiac manifestations<sup>5,6</sup>

- Fatigue
- Dyspnea upon exertion
- Syncope
- Conduction abnormalities
- Cardiac hypertrophy
- Diastolic dysfunction



## DIAGNOSTIC WORKUP<sup>4,7,a</sup>

Several types of tests can help identify the signs of hATTR amyloidosis.  
Diagnosis does not require all of these assessments.

### Sensory-motor assessments

- Electromyography (EMG)
- Nerve conduction study (NCS)

### Autonomic assessments

- Heart rate deep breathing
- Tilt table

### Cardiac assessments

- Electrocardiography (ECG)
- Echocardiography (Echo)
- Cardiac magnetic resonance imaging (CMRI)



## CONFIRMATORY TESTING<sup>2,4,5,8</sup>

Genetic testing  
Tissue biopsy + Congo red<sup>b</sup>  
Scintigraphy (for patients with cardiac involvement)<sup>a</sup>

<sup>a</sup>See page 2 for findings associated with hATTR amyloidosis and a scintigraphy algorithm for diagnosis.

<sup>b</sup>Sensitivity of biopsy can vary by site; negative biopsy may not always rule out hATTR amyloidosis.<sup>2</sup>

GI=gastrointestinal; hATTR=hereditary transthyretin-mediated; UTI=urinary tract infection.

# Findings consistent with hATTR amyloidosis

## Neurologic findings<sup>1,4,7</sup>


- Axonal length-dependent sensory-motor neuropathy<sup>a</sup>
- Small-fiber sensory neuropathy may progress to large-fiber sensory and motor neuropathy<sup>a</sup>
- Bilateral carpal tunnel syndrome
- Abnormal hemodynamic response and reduced heart rate variability in autonomic testing (e.g., orthostatic hypotension)

## Cardiac findings<sup>3,6</sup>

- Left ventricular wall thickening, refractile myocardium (granular sparkling) on echocardiogram
- Reduced longitudinal strain that may be more pronounced at the base than the apex
- Low voltage or progressive reduction in QRS voltage over time or pseudo-infarction pattern and/or atrioventricular block on ECG
- Subendocardial late gadolinium enhancement on CMRI

# Use of scintigraphy to detect amyloid deposition in the heart

Scintigraphy with technetium-labeled bone tracers is a noninvasive method for detection of amyloid deposits in the heart.<sup>8,9</sup>



Genetic testing and tissue biopsy can also be used to confirm a diagnosis of hATTR amyloidosis.

Adapted from Gillmore JD, et al. 2016.

<sup>a</sup>EMG and NCS may be normal in early stages of the disease.

<sup>b</sup>If preferred, monoclonal protein (serum, urine) testing can be done prior to <sup>99m</sup>Tc-PYP scintigraphy scan.

<sup>99m</sup>Tc-PYP=technetium-<sup>99m</sup>-pyrophosphate; AL=amyloid light chain; ATTR=transthyretin-mediated; hATTR=hereditary ATTR; wtATTR=wild-type ATTR.



Because progressive polyneuropathy also occurs in hATTR amyloidosis, evaluation for signs and symptoms of sensory-motor and autonomic neuropathy should be conducted.<sup>4</sup>

**References:** 1. Conceição I, González-Duarte A, Obici L, et al. *J Peripher Nerv Syst.* 2016;21(1):5-9. 2. Adams D, Koike H, Slama M, et al. *Nat Rev Neurol.* 2019;15(7):387-404. 3. Maurer MS, Elliott P, Comenzo R, et al. *Circulation.* 2017;135(14):1357-1377. 4. Ando Y, Coelho T, Berk JL, et al. *Orphanet J Rare Dis.* 2013;8:31. 5. Adams D, Suhr OB, Hund E, et al. *Curr Opin Neurol.* 2016;29(suppl 1):S14-S26. 6. Dharmarajan K, Maurer MS. *J Am Geriatr Soc.* 2012;60(4):765-774. 7. Shin SC, Robinson-Papp J. *Mt Sinai J Med.* 2012;79(6):733-748. 8. Gillmore JD, Maurer MS, Falk RH, et al. *Circulation.* 2016;133(24):2404-2412. 9. Dorbala S, Ando Y, Bokhari S, et al. *J Nucl Cardiol.* 2019;26(6):2065-2123.